European Patent Office rules in favor of Sanofi and Regeneron concerning Praluent.
Related news and insights
Amgen announced top-line results from two Repatha (evolocumab) open label extension (OLE) studies to the Phase III FOURIER cardiovascular outcomes trial. The studies were designed to assess the long-term safety and tolerability of Repatha over five years in adults with clinically evident atherosclerotic cardiovascular disease.
Pfizer and Ionis Pharmaceuticals announced the discontinuation of the Pfizer-led clinical development program for PF 07285557 (vupanorsen), an investigational antisense therapy that was being evaluated for potential indications in cardiovascular (CV) risk reduction and severe hypertriglyceridemia (SHTG).